Esperion (NASDAQ:ESPR) Therapeutics, Inc. (NASDAQ:ESPR) Chief Commercial Officer, Eric Warren, recently sold company shares to cover tax liabilities. The transaction, which took place on May 17, 2024, involved the sale of 192 shares of common stock at a price of $2.483 per share, totaling approximately $476.
The sale was made to satisfy tax obligations related to vested shares of restricted stock units, as indicated in the footnotes of the filing. Following the transaction, Warren's holdings in Esperion Therapeutics stand at 168,126 shares of common stock.
Investors often monitor insider transactions as they can provide insights into an executive's confidence in the company's prospects. In this case, the sale was not a market-driven decision but a necessary step to fulfill tax requirements.
Esperion Therapeutics, headquartered in Ann Arbor, Michigan, specializes in pharmaceutical preparations and continues to be a subject of interest for those following the healthcare sector.
InvestingPro Insights
Amidst the recent insider transaction at Esperion Therapeutics, Inc. (NASDAQ:ESPR), where Chief Commercial Officer Eric Warren sold shares to cover tax liabilities, the company's financial metrics and analyst projections provide a broader context for investors. According to InvestingPro data, Esperion's market capitalization currently stands at approximately $469.86 million, reflecting the scale of the business in the pharmaceutical industry.
An impressive surge in revenue growth is evident, with a remarkable 183.74% increase over the last twelve months as of Q1 2024, and an even more staggering quarterly revenue growth of 466.14% in Q1 2024. This significant rise indicates a strong expansion in the company's sales which aligns with the InvestingPro Tip that analysts anticipate sales growth in the current year. Despite the absence of profitability over the last twelve months and analysts not expecting the company to be profitable this year, Esperion's gross profit margin remains robust at 52.2%, suggesting effective cost management relative to its revenue.
Investors tracking the stock's performance will note the strong return over the last month, with a 21.03% increase, and a substantial price uptick over the last six months, boasting a 93.44% total return. These figures, combined with the InvestingPro Tip that three analysts have revised their earnings upwards for the upcoming period, may offer a positive outlook for the near future.
For those interested in further insights and additional InvestingPro Tips, there are currently 7 more tips available for Esperion Therapeutics, which can be accessed through InvestingPro. To deepen your analysis and make more informed decisions, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. This offer can provide investors with a comprehensive set of tools and data to evaluate Esperion's potential as an investment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.